ARCHIMED

About ARCHIMED

ARCHIMED is a French private equity firm exclusively dedicated to healthcare with €9.0 billion of assets under management as of December 2024, founded in 2014 and headquartered in Lyon with additional offices in Paris, London, New York, Milan and Munich. The firm is one of the few European private equity platforms focused entirely on healthcare verticals, providing depth of sector expertise across pharmaceuticals, medical technologies and life sciences services that generalist mid-cap funds cannot match.

Investment thesis

ARCHIMED targets European and selectively North American healthcare companies across MedTech, Pharma services, HealthTech, Biotech and broader healthcare services, deploying capital through dedicated flagship funds (MED Platform I, II and follow-on vintages) plus a Eureka small-cap programme for emerging healthcare companies. Equity ticket sizes typically range from €50 million to €300 million for the flagship strategy, with majority and significant minority equity positions held through five to seven year horizons. The healthcare sector-exclusive focus enables deep operational expertise, regulatory navigation and management team networks unique to medical-device, pharma and HealthTech businesses.

Recent activity

Recent realised exits include Ametris / ActiGraph (HealthTech, 2026), CARSO (MedTech, 2025), Citieffe (MedTech, 2025), DIESSE (MedTech, 2025), Ad-Tech Medical Instrument (MedTech, 2024) and Deallus (Pharma, 2024), demonstrating strong distribution momentum across the medical device and pharma services verticals. The platform tracks 6 funds, 36 active portfolio companies and 15 realised exits, with ongoing deployment from the latest flagship vintage across European and North American healthcare targets. Detailed buyer names and multiple data available on Pro at €29/month.